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Abstract
Introduction: Toxoplasmosis, a zoonotic protozoal disease caused by toxoplasma gondii, is prevalent
throughout the world, affecting a large proportion of persons who usually have no symptoms.
Glucose 6 phosphate dehydrogenase deficiency, an X-linked inherited disorder, is present in over
400 million people world wide. It is more common in tropical and subtropical countries and is one of
the important causes of hemolytic anemia.
Case presentation: This case report relates the occurrence of the two diseases simultaneously in
a child of five years old.
Conclusion: Patients with glucose-6-phosphate dehydrogenase deficiency are more susceptible
to toxoplasmosis and this case report, reinforce the findings of this propensity and alert us for
such possibility, what it is important, therefore, the treatment of toxoplasmosis can cause serious
hemolysis in these patients.
Introduction
Toxoplasmosis is a disease generated by toxoplasma gondii,
a protozoan parasite that infects up to a third of the world's
population. Infection is mainly acquired by ingestion of
food or water that is contaminated with oocysts shed by cats
or by eating undercooked or raw meat containing tissue
cysts. Primary infection is usually sub-clinical but in some
patients, cervical lymphadenopathy or ocular disease can be
present. In most adults and children it does not cause
serious illness, but it can cause blindness and mental
retardation in congenitally infected children and devastat-
ing disease in immunocompromised individuals [1,2].
There is report of precocious puberty as an endocrine
manifestation in congenital toxoplasmosis [3].
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency,
the most common enzyme deficiency worldwide, causes
a spectrum of disease including neonatal hyperbilirubi-
nemia, with acute and chronic hemolysis. Persons with
this condition also may be asymptomatic. This X-linked
inherited disorder most commonly affects persons of
African, Asian, Mediterranean, or Middle-Eastern descent.
Approximately 400 million people are affected worldwide
[4,5].
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Here is related a case of patient with acquired toxo-
plasmosis and glucose-6-phosphate dehydrogenase
simultaneously.
Case presentation
A 5 years old male child, white race, natural of Minas Gerais
State, Brazil, presented with fatigue, malaise and low-grade
fever at least 10 days. Examination revealed: pallor, painless
axillary and cervical lymphadenopathy and splenohepa-
tomegaly. His hemogram showed leucocytosis with
anemia [Hb = 8.0 gm%, WBC = 28,200 cells/cumm (51%
polymorphs and 49% lymphocytes)], his liver function
tests were normal. At the thirteen day a clinical diagnosis of
toxoplasmosis was considered, an enzyme-linked immu-
noassay (ELISA) for toxoplasma antigens in blood showed
IgM = 1:256 and IgG = 1:1024. Ahead of the results the
treatment with pyrimethamine 1 mg/kg/d plus sulfadiazine
(100 mg/kg/day), plus folinic acid was initiated.
In the seventh day of treatment the patient presented
important jaundice and dark urine beyond decreased urine
output, in the physical examination was observed, impor-
tant splenohepatomegaly, tachycardia and tachypnea.
A clinical diagnosis of acute hepatitis secondary to
medications was considered. Laboratory exams showed:
hemoglobin 6.4 gm%, WBC = 10,200 cells/cumm, serum
bilirubin = 1.4 mg/dl with indirect bilirubin = 0.9 mg/dl,
liver enzymes were normal, thus, a clinical diagnosis of
acute hemolysis was considered and new examinations had
shown reticulocyte count = 5.1%with corrected reticulocyte
count = 1.7%, direct coombs test and indirect coombs test
being negative, urine routine examination showed was
normal with absent bile salts and bile pigments and urine
culture did not show any organism. A smear of the blood
showed an important degree of hemolysis (Figure 1). The
patient was screened for G-6-PD activity, which was absent.
Thus a diagnosis of acute acquired toxoplasmosis with
G-6-PD deficiency was considered with acute hemolysis due
to sulfadiazine ingestion.
The sulfadiazine was discontinued and the treatment was
changed for clindamycin so the patient was discharged
without jaundice with hemoglobin 10.0 gm% and
reticulocyte count = 0.5%. On follow up after 1 month,
his hemoglobin was 12.5 gm%.
The parents of patient were advised to avoid antimalarials,
sulfa drugs, chloramphenicol, nitrofurantoin, nalidixic
acid, Vitamin K and others drugs due to his G-6-PD
deficiency state.
Discussion
An unusual propensity for infection with catalase-positive
organisms has been reported in patients with severe
deficiency or complete absence of G-6-PD [4-6], however,
propensity for infection with toxoplasma gondii was
reported in only in a study [6] which showed an increased
risk of toxoplasma infection by 2.5 folds in persons with
G-6-PD deficiency as compared to G-6-PD normal
individuals. The likely explanation for the increased
infection rate is due to both direct destruction of the
reticuloendothelial system by toxoplasma organisms and
decreased killing effect of the phagocytic cells [6,7].
In this case report the presence of the two diseases in a
child, reinforce the findings of this propensity and alert us
for such possibility, mainly considering the high pre-
valence of the two illnesses in the world. World-wide
prevalence of toxoplasmosis varies of 2.3% to 93%, while
that the prevalence of G-6-PD deficiency varies of 0 to
27%, so, ahead of the necessity of treatment for
toxoplasmosis this fact must be taken in consideration,
for the possibility of hemolysis secondary to sulfas.
Clinical presentations of G-6-PD deficiency are secondary
at some factors such as infections, intake of fava beans,
antimicrobial drugs, mainly sulfas and its derivatives. In
the case above reported, the patient was using sulfadiazine
for treatment of toxoplasmosis and developed acute
hemolysis, at which quickly decreased after removed of
the medicine and its exchange for clindamycin, at which is
usually recommended for treatment of toxoplasmosis in
specials situations [6-8].
Abbreviations
G-6-PD, Glucose-6-phosphate dehydrogenase; WBC,
white blood cells.
Consent
Written informed consent was obtained from parents of
the patient for publication of this case report and
Figure 1. Hemolysis due to G-6-PD deficiency in a child of
five years old.
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accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
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